BioRestorative Therapies (BRTX)

• Market cap: $10.7M
• 1 day: 6.90%
• 5 days: 6.16%
• 1 month: 10.71%
• 3 months: -19.27%
• 6 months: -25.84%
• Year to date: -9.88%
• 1 year: -11.43%
• 5 years: -77.92%
• 10 years: -77.92%
• Sector: Healthcare
• Industry: Miscellaneous Health & Allied Services

About: BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.

Employees: 11

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

15% more funds holding

Funds holding: 13 [Q2] → 15 (+2) [Q3]

0.01% less ownership

Funds ownership: 3.9% [Q2] → 3.9% (-0.01%) [Q3]

13% less capital invested

Capital invested by funds: $537K [Q2] → $468K (-$69.4K) [Q3]

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4